Frequency of *EGFR* Mutations in 907 Lung Adenocarcinoma Patients of Indian Ethnicity

Anuradha Chougule\(^1\)*, Kumar Prabhash\(^1\), Vanita Noronha\(^1\), Amit Joshi\(^1\), Abhishek Thavamani\(^2\), Pratik Chandrani\(^2\), Pawan Upadhyay\(^2\), Sagarika Utture\(^3\), Saral Desai\(^3\), Nirmala Jambhekar\(^3\), Amit Dutt\(^2\)*

\(^1\) Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, Maharashtra, India, \(^2\) Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Navi Mumbai, Maharashtra, India, \(^3\) Department of Pathology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, Maharashtra, India

**Abstract**

**Background:** During the past decade, the incidence of *EGFR* mutation has been shown to vary across different ethnicities. It occurs at the rate of 10–15% in North Americans and Europeans, 19% in African-Americans, 20–30% in various East Asian series including Chinese, Koreans, and Japanese. Frequency of *EGFR* mutations in India however remains sparsely explored.

**Methodology/Principal Findings:** We report 23% incidence of *Epidermal growth factor receptor (EGFR)* mutations in 907 Non small cell lung cancer (NSCLC) patients of Indian ethnicity, in contrast to 10–15% known in Caucasians and 27–62% among East Asians. In this study, *EGFR* mutations were found to be more common in never-smokers 29.4% as compared to smokers 15.3%. Consistent with other populations, mutation rates among adenocarcinoma-males were predominantly lower than females with 32% incidence. However unlike Caucasians, *EGFR* mutation rate among adenocarcinoma-never-smoker females were comparable to males suggesting lack of gender bias among never smokers likely to benefit from *EGFR* targeted therapy.

**Conclusions/Significance:** This study has an overall implication for establishing relevance for routine *EGFR* mutation diagnostics for NSCLC patients in clinics and emphasizes effectiveness for adoption of *EGFR* inhibitors as the first line treatment among Indian population. The intermediate frequency of *EGFR* mutation among Indian population compared to Caucasians and East Asians is reminiscent of an ancestral admixture of genetic influence from Middle Easterners, Central Asians, and Europeans on modern- Indian population that may confer differential susceptibility to somatic mutations in *EGFR*.

**Citation:** Chougule A, Prabhash K, Noronha V, Joshi A, Thavamani A, et al. (2013) Frequency of *EGFR* Mutations in 907 Lung Adenocarcinoma Patients of Indian Ethnicity. PLoS ONE 8(10): e76164. doi:10.1371/journal.pone.0076164

**Editor:** Balraj Mittal, Sanjay Gandhi Medical Institute, India

**Received** July 4, 2013; **Accepted** August 23, 2013; **Published** October 4, 2013

**Copyright:** © 2013 Chougule et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** A.D. is supported by an Intermediate Fellowship from the Wellcome Trust/DBT India Alliance (IA/I/11/2500278), by a grant from DBT (BT/PR2372/AGR/36/696/2011), and intramural grants (Seed-In-Air 2897, TMH Plan Project 2712 and IRB 92). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

* E-mail: kprabhash1@gmail.com (KP); adutt@actrec.gov.in (AD)

\(^*\) These authors contributed equally to this work.

**Introduction**

In India, and worldwide, lung cancer is the leading cause of cancer mortality. About 63 thousand new cases are diagnosed each year in India with deaths estimated at approximately 52,000, accounting for about 8% of all cancer deaths [1,2]. The majority of lung cancer cases are non-small cell lung cancers (NSCLC), which accounts for approximately 85% of all lung cancer cases. Of the available therapeutic options, chemotherapy for NSCLC has been only marginally effective. Development of new and effective therapy therefore has been and continues to be a major public health imperative. Among a multitude of targeted agents explored for the treatment of advanced NSCLC, small molecule tyrosine kinase inhibitors (TKI), gefitinib and erlotinib, targeting a mutant epidermal growth factor receptor (EGFR) have shown significant benefit in clinics. Activating *EGFR* mutations in the tyrosine kinase region have been shown to underlie response to these inhibitors, and have become an established predictive marker to select NSCLC patients for treatment [3–5]. FDA approved EGFR inhibitors as the first line of treatment for advanced NSCLC patients positive for *EGFR* activating mutation [6,7], but not for patients with wild-type *EGFR*, wherein in contrast an inferior outcome is observed in response to the treatment [8,9]. Thus, an accurate incidence of *EGFR* mutation findings is critical to reckon the effectiveness for adoption of gefitinib as first line of treatment for *EGFR*-activating mutation-positive advanced NSCLC patients in any given population.

During the past decade, the incidence of *EGFR* mutation in NSCLC has been shown to vary across different ethnicities. It occurs at the rate of 10–15% in North Americans and Europeans [3,4,10], 19% in African-Americans [11], 26–30% in various East Asian series including Chinese [12], Koreans [13], Japanese [14], and as compiled in Table 1 (adapted from [15]). Frequency of *EGFR* mutations in India however remains sparsely explored. Although, there are three reports from India with mutation rate...
varying between 22–51.8%, they tend to overestimate the incidence of EGFR mutation, because of a small sample size and clinically selected patients [16–18]. Here, in this study we determine clinically selected patients. Here, in this study we determine EGFR mutation rate in 907 NSCLC patients of Indian ethnicity and correlate across different variables of age, gender, habits and histology groups.

**Materials and Methods**

This study is a retrospective analysis on all the patients who were referred for EGFR testing from medical oncology department at the Tata Memorial Hospital, Mumbai as a routine service over a 1.5 year period. This was part of standard care: when referred for EGFR genotyping, the diagnosis of adenocarcinoma or squamous cell carcinomas were made on histomorphological grounds in cases where the appearances were characteristic, or immunohistochemistry staining were performed using antibodies against TTF1, P53, Napsin A, and CK 5/6. As a routine practice, 2 or more antibodies were used to distinguish adenocarcinoma from squamous carcinoma. Smoking history was recorded by directly asking specific question to all the patients at the Medical Oncology Department, Tata Memorial Hospital. The Institutional Review Board (IRB) and the Ethics Committee (EC) of Tata Oncology Department, Tata Memorial Hospital. The patient characteristics including the age, gender, smoking/tobacco use and histopathology were recorded.

**Collection of Patient Samples**

The paraffin embedded FFPE blocks of the patients were collected from the pathology department, at the Tata Memorial Hospital. The hematoxylin and cosin stained sections of the blocks were mounted on slides and viewed under the microscope to confirm that the tumor – region constitutes more than 75% of the tissue mass.

| Region              | Incidence | Overall Mutation Rate |
|---------------------|-----------|-----------------------|
| Vietnam             | 77/120    | 64.2%                 |
| Japan               | 21/263    | 27%                   |
| East Asia           | 107/361   | 30%                   |
| Taiwan              | 108/174   | 62.1%                 |
| Thailand            | 63/117    | 53.8%                 |
| Philippines         | 34/65     | 52.3%                 |
| China               | 372/741   | 50.2%                 |
| Hong Kong           | 76/161    | 47.2%                 |
| United States of America | 11/80    | 14%                   |
| Australia           | 6/83      | 7%                    |
| India - Chennai     | 16/72     | 22.2%                 |
| India (Tata Memorial Hospital) | 202/780 | 26%                   |

**Table 1. Molecular Epidemiological status of EGFR mutation (adapted [15]).**

DNA Extraction

For DNA isolation, six FFPE tissue sections of 14 μm each were taken, using microtome (Leica). After deparaffinizing the sections with Xylene, the DNA was extracted as per the kit insert (QiaAmp FFPE tissue kit, Cat no 56404) and as described earlier [19].

**Mutation Analysis by PCR and Sequencing**

Extracted DNA was amplified for the exons 18, 19, 20 and 21 using a nested-PCR method [20], with a 100 ng DNA as the template. With the above PCR products as template, second round of nested PCR amplification was carried out using a different set of primers flanking the regions. The amplicons were then purified using the Qiaquick PCR purification kit (Qiagen). About 2.5 ng of the PCR product, along with 1.6 pmols of the forward or reverse primer was used for sequencing in the Applied Biosystems DNA Analyser, as described earlier [21]. The resulting sequence was compared to the available normal sequence in the NCBI database using the NCBI BLAST and the variations observed thereupon were recorded.

**Mutation Analysis by TaqMan based Real Time PCR Technique**

The reaction mixture was carried out in 10 μL volumes, which contains 5 μL of the Taqman probe, master mix (Roche), primers at a final concentration of 9 μM and probes at a final concentration of 2 μM and the remaining volume was made up to 5 μL using PCR grade water using LC 480 II machine. The program used was, 50°C for 2 minutes and 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. The detectors used were FAM/VIC at 5′ and TAMRA/MGB at 3′ fluorescence for the wild type and mutant respectively. The Assay sensitivity has a limit of 1% detection and each run consisted of a positive and a negative control to check the integrity of the assay.

**Statistical Analysis**

The Chi-square test was performed to reveal any significant correlation between the mutation status and age, gender and habits of the patient and tumor histology.

**Results**

**Clinical Testing for EGFR Exon 18–20 in 907 Consecutive Cases**

907 patients diagnosed with lung cancer in Tata Memorial Hospital from August 2011 to December 2012 were tested for common EGFR mutation subtypes by real time PCR using TaqMan primer probes for point mutations in exon 18 and 21, and an in frame deletion in exon 19. Exon 20 point mutation assay was incorporated from August 2012 onwards in 215 cases. After standardization and validation by sanger based directed sequencing for the robustness and sensitivity of the real time PCR, it was implemented as the routine diagnostic test (data not shown). As shown in Table 2, of the 907 patients tested, there were 642 males and 265 females with a ratio of 2.4:1. The median ages of male and female population’s were 57 and 54 years respectively. No data of smoking habit was available in 31 males. In the group of <40 years, there were only 12 male smokers out of 92. Within the different age group the mutation rate was marginally high in >60 yrs as compared to age of ≤60 yrs (26.8% vs 21%). The total population of smoker vs never-smoker was 39.6% vs 56.8% with a p value of <0.001 (Table 3). Overall mutation rate was 23.2% with a higher mutation rate in females as compared to males.
Association of EGFR Mutations with the Smoking Status of the Patients

There were equal numbers of never-smoking in both genders i.e. 258, this number in both the groups allowed us to adequately compare the two groups. EGFR mutation rate was more prevalent in the never-smoker than the smoker group (29.4% vs 15.3%) with a p value of <0.001 (Table 3; and Fig. 1). However, it was almost equivalent in the never-smoker group of males and females (28.3% vs. 30.6%), as shown in Fig. 1.

Association between EGFR Mutation and Clinicopathological Status of the Patients

Majority of the histological diagnoses examined were adenocarcinoma (88.0%), followed by squamous cell carcinomas (11.6%) and adenosquamous carcinomas (1.5%) (Table 2). The overall frequency of EGFR mutations in adenocarcinoma population was 26% as compared to 3.8% in squamous cell carcinomas (Table 3; and Fig. 1). Interestingly, mutation rate was predominantly higher among women than male adenocarcinomas (32% vs 23%) but there was no significant difference between never-smoker female and male (32% vs 30%) adenocarcinomas. Of all the EGFR TK domain mutations 50% were in-frame deletions in exon 19, while 42% were missense mutations in exon 21, 7% of the mutations are reported in exon 18 and 3% in exon 20 with two patients harboring mutation in exon 20 along with exon 21.

Discussion

Many countries have already adopted in practice testing for EGFR mutations to determine appropriate treatment with EGFR inhibitors. While there are still some uncertainties whether the superior outcome observed in the clinical trials are generalizable across different ethnicities, different countries continue to evaluate clinical utility and cost-effectiveness of these inhibitors. We recently showed 74% response rate to oral tyrosine kinase inhibitor among Indian NSCLC patients with activating mutation of EGFR compared to 5% among patients with wild type EGFR, emphasizing EGFR mutation as an important predictive marker for response to oral tyrosine kinase inhibitors in a clinically selected small cohort of 111 patients of Indian origin [16]. It is thus imperative to know the mutation rates of this biomarker accurately by involving larger unbiased sample size to allow adequate statistical power for analysis. This study of 907 patients (largest

Table 2. Patient Demographics.

| N = 907 | Variables | Smokers | Non-smokers | NA |
|---|---|---|---|---|
| No of Patients | 360 (39.6%) | 516 (56.8%) | 31 (3.4%) |
| Mean Age | 58.14 | 52.9 | 54.7 |
| Age | <40 yrs | 12 | 76 | 4 |
| | 40–60 yrs | 180 | 277 | 18 |
| | >60 yrs | 168 | 163 | 9 |
| Gender | Male | 353 | 258 | 31 |
| | Female | 7 | 258 | 0 |
| Histopathology | Adenocarcinoma | 277 | 477 | 26 |
| | Squamous | 74 | 26 | 3 |
| | Adenosquamous | 5 | 6 | 2 |
| | Others | 4 | 7 | 0 |

Table 3. Frequency and Overall mutation rate of different variables in NSCLC.

| Variables | Mutations | Total | Percentage | Significance |
|---|---|---|---|---|
| Over all Mutation Rate | 210 | 907 | 23.0% | 0.002 |
| Male | 131 | 642 | 20.4% |
| Female | 79 | 265 | 29.8% |
| Smoking status | | | | <0.001 |
| Smokers | 55 | 360 | 15.3% |
| Never smokers | 152 | 516 | 29.4% |
| Not available | 3 | 31 | 9.7% |
| Histopathology | | | | <0.001 |
| Adenocarcinomas | 202 | 780 | 25.9% |
| Squamous | 4 | 103 | 3.8% |
| Others | 4 | 24 | 16.7% |
| Gender with histopathology | | | | 0.01 |
| Male adenocarcinomas | 123 | 531 | 23.0% |
| Female adenocarcinoma | 79 | 249 | 32.0% |
| Gender with smoking status | | | | 0.56 |
| Never smoker male | 73 | 258 | 28.3% |
| Never smoker female | 79 | 258 | 30.6% |
| Histopathology with smoking status and gender | | | | 0.58 |
| Adenocarcinomas never smoker male | 70 | 233 | 30.0% |
| Adenocarcinomas never smoker female | 79 | 244 | 32.0% |

doi:10.1371/journal.pone.0076164.t002
doi:10.1371/journal.pone.0076164.t003
single cohort study from India] showed an overall 23% EGFR mutation, with a rate of 26% in adenocarcinoma, in Indian population that closely approximates the rate in Japanese and East Asian countries. We found a higher rate of EGFR mutation in adenocarcinomas than over all (29.8% vs 20%) and among women than men (32% vs 23%), similar to Korean, Chinese and Japanese data as reported earlier [1,13–15] (Table 1). EGFR mutations have been consistently reported to be more common in never-smokers as compared to smokers [11], which our study confirms as well (29.4% vs 15.3%). Though, the mutation rate varies significantly between never-smokers and smokers across different ethnicities. For e.g., 47% never smokers harbor EGFR mutations compared to 22% among smokers in the Chinese population; among other Asian series, mutation rate among never-smokers have been reported to be as high as 60%; among European descent, 22% Italians and 38% Spanish never-smokers series were reported to be EGFR mutation positive compared to 8% smokers [11,22]. Histopathologically, mutation rates among adenocarcinoma-males were predominantly lower than females, consistent with literature. However, no significant difference were observed between never-smoker adenocarcinoma females and males indicating lack of gender bias among never-smoker patients, possibly due to lower proportion of male non smokers (258 non smokers out of 516 males) exists in India compared to female non smokers (258 non smokers out of 265 females), unlike in developed countries. This is also consistent with similar studies on never-smoker females of East Asian ethnicity [23–25], wherein rate of mutation varies with clinical stage of never-smoker female patients [26]. Among the squamous cell lung carcinomas, there have been few studies within East Asians with conflicting results: two study from China reported EGFR mutation rate of 21% (3/14) and 13.3% (4/30) compared to a Korean based study with 7.3% (3/41) [27–29]. We found EGFR mutation rate of 3.8% in this largest cohort of squamous cell carcinoma study reported so far, n = 103, which is surprisingly more similar to incidence as observed in the west. Taken together, this study emphasizes that EGFR mutation text for squamous cell carcinoma need to as well be considered as a routine practice, as recommended for ALK mutations with comparable incidence at around 5% [30].

Our findings of exon 18, 19 and 21 with a mutation rate of 7%, 50% and 42% respectively is similar to that described in Spanish and Japanese populations [22,31–35]. In our earlier study, exon 19 mutation was present in 67% cases and exon 21 in 29% of cases, this difference could be because of the smaller sample size of 111 patients [16]. Within the cohort of different mutations, we analyzed the clinical and pathological characteristics of lung adenocarcinoma patients. Our results suggest that exon 21 mutations are more common in never-smoker females than males, whereas exon 19 showed marginally higher mutation rate in never smoker males than females. It has been reported that exon 18 EGFR mutations are detected more frequently in younger patients, which was also noted in our study [32]. Of note, some other studies have also observed no association between EGFR mutations and age, gender or smoking history in Chinese patients [23]. Furthermore, the analysis involving exon 20 mutations, performed in 215 out 907 patients, identify 3% incidence similar to the reported literature [35].

A major limitation of this study is the lack of survival data. Since the cases were collected from 2011 to 2012, survival data of these patients were far from maturity. While we recently reported clinical correlation to EGFR mutation status on a retrospectively collected smaller independent cohort of 111 patients, it would be of interest to validate the prognostic impact of clinical variables, histologic patterns, and mutation types on these 907 patients. In summary, western series show a mutation rate of 10–15% [4,10] and East Asian population show a heterogeneous mutation rate of 27–62% [22,34,35]. Mutation rate of 23% in EGFR among Indian population is less than that of East Asian patients and more than Western patients. This finding is interestingly reminiscent of the historical evidence for amalgamation of major ancestral populations over past thousand of years in India creating an admixture of genetic influence from Middle Easterners, Central Asians, and Europeans due to different degree of migration wave at different points of time in the Indian history [36]. Furthermore, this study could plug the crucial deficit in establishing gradient incidence of EGFR mutation across ethnicities and help inform designing of genome wide association studies to determine haplotype that may confer differential susceptibility to somatic mutations in EGFR in NSCLC, as reported for somatic mutations in JAK2 in human myeloproliferative neoplasms [37].
Acknowledgments
Sanjay Talode, for statistical analysis. Dr. Rajiv Sarin and Dr. Shriraj Banavali for thoughtful insights and discussion.

References
1. Noronha V, Dikshit R, Raut N, Joshi A, Pramesh CS, et al. (2012) Epidemiology of lung cancer in India: focus on the differences between nonsmokers and smokers: a single-centre experience. Indian J Cancer 49: 74–81.
2. Feral J, SH, Ray F, Forman D, Mathers C and Parkin DM. (2010) GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer Available: http://globocan.iarc.fr. Accessed 2013 Jul 2.
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139.
4. Paez JG, Jaume PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500.
5. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306–13311.
6. Rosell R, Carcereny E, Vervaeke R, Vergnenegre A, Massuti B, et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239–246.
7. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735–742.
8. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947–957.
9. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 938–947.
10. Dogan S, Shen R, Arg DC, Johnson ML, D’Angelo SP, et al. (2012) Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 18: 6169–6177.
11. Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, et al. (2005) Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 16: 1081–1086.
12. Reinersman JM, Johnson ML, Richy GJ, Chitale DA, Nicastri AD, et al. (2011) Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol 6: 28–31.
13. Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L, et al. (2007) Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2: 430–439.
14. Kim HJ, Oh SY, Kim WS, Kim SJ, Yoo GH, et al. (2013) Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients. Oncol Lett 5: 271–276.
15. Pan-Chyr Yang YS, Joseph Su-kin,Aurrt AI (2012) Molecular epidemiological prospective study of EGFR mutations from Asian patients (pts) with advanced lung adenocarcinoma. J Clin Oncol 30.
16. Noronha V, Prabhakar K, Thavamani A, Chouqule A, Parandae N, et al. (2013) EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted Therapy. PLoS One 8: e61561.
17. Sahoo R, Harini VV, Babu YC, Patil Okaly GV, Rao S, et al. (2011) Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer 73: 316–319.
18. ShyamAggarwal S, SachinMinhans, Manish Punglua, Soumitra N (2012) A study of EGFR mutation in nonsmoker NSCLC: Striking disparity between north and south India patients. J Clin Oncol 30, 2012 (suppl, abstr e10041).
19. Cronin M, Phe M, Dutta D, Stephens JC, Shak S, et al. (2004) Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92–gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 164: 33–42.
20. Molina-Vila MA, Bertran-Alamillo J, Reguani N, Taron M, Castella E, et al. (2008) A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol 3: 1224–1235.
21. Endo K, Konishi A, Susaki H, Takakda M, Tanaka H, et al. (2005) Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 50: 375–384.
22. Tomizawa Y, Iijima H, Sunaga N, Sato K, Takise A, et al. (2005) Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 11: 6816–6822.
23. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, et al. (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 9019–9023.
24. Sun YH, Fang R, Gao B, Han XK, Zhang JH, et al. (2010) Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers. Acta Pharmacol Sin 31: 647–648.
25. Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, et al. (2010) Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 126: 651–653.
26. Zhang Y, Sun Y, Pan Y, Li C, Shen L, et al. (2012) Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res 18: 1947–1953.
27. Lee JW, Soong YH, Kim SY, Nam HK, Park WS, et al. (2005) Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11: 2879–2882.
28. Li M, Zhang Q, Liu L, Liu Z, Zhou L, et al. (2011) The different clinical significance of EGFR mutations in exon 19 and 21 in non-small cell lung cancer patients of China. Neoplasma 58: 74–81.
29. Sun MH, Yang F, Shen I, Zhang L, Chen Y, et al. (2011) [Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types]. Zhonghua Bing Xue Za Zhi 49: 635–659.
30. Lindeman NI, Cagle PT, Beailey MB, Chitale DA, Dacic S, et al. (2013) Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn.
31. Gazdar AF (2009) Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28 Suppl 1: S24–31.
32. Huang SF, Liu HP, Li LY, Zhang XT, Zhang L, et al. (2007) Clinical and biological features associated with epidermal growth factor receptor gene in patients with non-small cell lung cancer related to gefitinib responsiveness in Taiwan. Clin Cancer Res 13: 957.
33. Kawamura H, Michalek J, Proctor C, Kourany P, L過去鑑 R, et al. (2001) A sensitive method for detecting EGFR mutations in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 50: 375–384.
34. Okuyama D, Harutyunyan A, Jaeger B, Berg T, Gisslinger B, et al. (2009) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 41: 450–454.

Author Contributions
Conceived and designed the experiments: AC KP VN NJ AD. Performed the experiments: AC KP VN AJ AT PC PU SU SD NJ AD. Wrote the paper: AC KP AD.